Novel thrombolytic agents

[1]  D. Behnke,et al.  Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase — a bacterial plasminogen activator , 1987, Molecular and General Genetics MGG.

[2]  T. Sako,et al.  Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli , 2004, Molecular and General Genetics MGG.

[3]  H.,et al.  A Monoclonal Antibody Specific for Two-Chain Urokinase-Type Plasminogen Activator . Application to the Study of the Mechanism of Clot Lysis With Single-Chain Urokinase-Type Plasminogen Activator in Plasma , 2003 .

[4]  U. Tebbe,et al.  Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). , 1994, Journal of the American College of Cardiology.

[5]  P. Declerck,et al.  Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase , 1994, Thrombosis and Haemostasis.

[6]  D. Collen,et al.  Coronary thrombolysis with K1K2PU, a chimeric tissue‐type and urokinase‐type plasminogen activator: A feasibility study in six patients with acute myocardial infarction , 1993, Coronary artery disease.

[7]  Stefan Fischer,et al.  Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. , 1993, Journal of the American College of Cardiology.

[8]  B. Keyt,et al.  A Variant of t-PA (T103N, KHRR 296-299 AAAA) that, by Bolus, Has Increased Potency and Decreased Systemic Activation of Plasminogen , 1993, Thrombosis and Haemostasis.

[9]  K. Silence,et al.  Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin. , 1993, The Journal of biological chemistry.

[10]  Y. Engelborghs,et al.  On the mechanism of the activation of human plasminogen by recombinant staphylokinase. , 1993, The Journal of biological chemistry.

[11]  F. Van de Werf,et al.  Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction , 1993, Circulation.

[12]  D. Collen,et al.  Comparative Immunogenicit and Thrombolytic Properties Toward Arterial and Venous Thrombi of Streptokinase and Recombinant Staphylokinase in Baboons , 1993, Circulation.

[13]  P. Declerck,et al.  Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase , 1992 .

[14]  P. Marynen,et al.  Primary Structure and Gene Structure of Staphylokinase , 1992 .

[15]  D. Collen,et al.  Biochemical-properties of natural and recombinant staphylokinase , 1992 .

[16]  W. Nichols,et al.  Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator. , 1992, Journal of the American College of Cardiology.

[17]  K. Strein,et al.  Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[18]  W. Schleuning,et al.  Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. , 1992, Blood.

[19]  K. Strein,et al.  Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. , 1992, Journal of the American College of Cardiology.

[20]  J. Lynch,et al.  Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  O. Matsuo,et al.  On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin-formula> and fibrin , 1992 .

[22]  K. Strein,et al.  Pharmacokinetics of the Novel Recombinant Plasminogen Activator BM 06.022 in Rats, Dogs, and Non-human Primates , 1992 .

[23]  O. Matsuo,et al.  Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro , 1992 .

[24]  C. Kawai.  Multicenter trial of a novel modified t-PA, E6010, by i.v.bolus injection in patients with acute myocardial infarction. , 1992 .

[25]  R. Rudolph,et al.  Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.

[26]  J. D. Frank,et al.  Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis. , 1992, The Journal of pharmacology and experimental therapeutics.

[27]  M. Scully.  PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS , 1991, British journal of haematology.

[28]  G. Agnelli,et al.  Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  K. Okada,et al.  Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis , 1991, Thrombosis and Haemostasis.

[30]  B. Kaufmann,et al.  Dose‐ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers , 1991, Clinical pharmacology and therapeutics.

[31]  L. Nelles,et al.  Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators , 1991, Circulation.

[32]  D. Collen,et al.  Strategies for the Improvement of Thrombolytic Agents , 1991, Thrombosis and Haemostasis.

[33]  R. Rudolph,et al.  Coronary Thrombolytic Properties of a Novel Recombinant Plasminogen Activator (BM 06.022) in a Canine Model , 1991, Journal of cardiovascular pharmacology.

[34]  B. Binder,et al.  Function of Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[35]  D. Collen,et al.  Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. , 1991, Blood.

[36]  S. Gardell,et al.  Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits , 1991, Circulation.

[37]  K. Okada,et al.  On the mechanism of fibrin-specific plasminogen activation by staphylokinase. , 1991, The Journal of biological chemistry.

[38]  R. Rudolph,et al.  Thrombolysis with an Escherichia coli-Produced Recombinant Plasminogen Activator (BM 06.022) in the Rabbit Model of Jugular Vein Thrombosis , 1991, Thrombosis and Haemostasis.

[39]  K. Okada,et al.  Thrombolytic properties of staphylokinase. , 1990, Blood.

[40]  L. Nelles,et al.  Characterization of Domain Deletion and/or Duplication Mutants of a Recombinant Chimera of Tissue-Type Plasminogen Activator and Urokinase-Type Plasminogen Activator (rt-PA/u-PAI) , 1990, Thrombosis and Haemostasis.

[41]  L. Poller.  Anticoagulant therapy with minidose warfarin: present results and possible implications , 1990 .

[42]  T. Quertermous,et al.  Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. , 1989, Journal of immunology.

[43]  O. Matsuo,et al.  Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor. , 1989, Biochemical and biophysical research communications.

[44]  T. Podor,et al.  Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. , 1989, The Journal of biological chemistry.

[45]  D. Collen,et al.  The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. , 1989, Blood.

[46]  A. Corti,et al.  Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells , 1989 .

[47]  M. Scully,et al.  Activation of pro-urokinase by plasmin: non-Michaelian kinetics indicates a mechanism of negative cooperativity. , 1989, Archives of biochemistry and biophysics.

[48]  L. Nelles,et al.  Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator. , 1988, The Journal of biological chemistry.

[49]  C. Hamm,et al.  Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. , 1988, The American journal of cardiology.

[50]  L. Nelles,et al.  Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. , 1988, The Journal of biological chemistry.

[51]  S. Hohnloser,et al.  Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. , 1988, Klinische Wochenschrift.

[52]  D. Rifkin,et al.  Cell-associated plasminogen activation: regulation and physiological functions. , 1988, Annual review of cell biology.

[53]  B. André,et al.  Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization. , 1987, The Journal of biological chemistry.

[54]  D. Collen,et al.  Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator. , 1987, The Journal of biological chemistry.

[55]  L. Nelles,et al.  Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. , 1987, The Journal of biological chemistry.

[56]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[57]  D. Collen,et al.  Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. , 1986, The Journal of biological chemistry.

[58]  M. Blaber,et al.  Activation of plasminogen by pro-urokinase. I. Mechanism. , 1986, The Journal of biological chemistry.

[59]  D. Collen,et al.  Activation of Plasminogen by Pro-urokinase , 1986 .

[60]  H. Heyneker,et al.  Cloning and Expression of the Gene for Pro-urokinase in Escherichia coli , 1985, Bio/Technology.

[61]  P. Verde,et al.  Human urokinase gene is located on the long arm of chromosome 10. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[62]  T. Sako.  Overproduction of staphylokinase in Escherichia coli and its characterization. , 1985, European journal of biochemistry.

[63]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[64]  D. Collen,et al.  Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys , 1984, Thrombosis and Haemostasis.

[65]  P. Verde,et al.  Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Z. Váli,et al.  Kringles: modules specialized for protein binding , 1984, FEBS Letters.

[67]  R. W. Scott,et al.  Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. , 1984, Journal of Biological Chemistry.

[68]  L. Ossowski,et al.  Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors. , 1983, Cancer research.

[69]  J. Zeuthen,et al.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.

[70]  L. Flohé,et al.  The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[71]  Bernik Mb,et al.  Plasminogen activator and proactivator (urokinase precursor) in lung cultures. , 1976 .

[72]  M. Bernik,et al.  Plasminogen activator and proactivator (urokinase precursor) in lung cultures. , 1976, Journal of the American Medical Women's Association.

[73]  A. S. Douglas,et al.  In vitro studies of staphylokinase. , 1965, Clinical science.

[74]  C. Kerber,et al.  EFFECTS OF FIBRINOLYTIC AGENTS AND HEPARIN ON INTRAVASCULAR CLOT LYSIS. , 1964, The American journal of physiology.

[75]  J. Lewis,et al.  A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase. , 1951, The American journal of physiology.

[76]  Brain Wr,et al.  Mind and matter. , 1951 .

[77]  C. Lack.  Staphylokinase: an Activator of Plasma Protease , 1948, Nature.